Secukinumab

The FDA has approved an intravenous formulation of Cosentyx for use in patients with psoriatic arthritis, ankylosing spondylitis and nonradiographic axial spondyloarthritis, according to a press release from Novartis.

Secukinumab and adalimumab demonstrate similar efficacy regarding the resolution of enthesitis over 52 weeks in patients with psoriatic arthritis, according to data published in Rheumatology.

The European Commission has approved Cosentyx in the European Union for the treatment of moderate to severe hidradenitis suppurativa in adults who do not respond to conventional therapy, Novartis announced in a press release.

The European Medicines Agency has issued a positive opinion of Cosentyx for the treatment of adults with moderate to severe hidradenitis suppurativa and recommends a marketing authorization be granted, Novartis announced in a release.

In this Healio video exclusive, Jashin J. Wu, MD, FAAD, discusses the benefits of switching patients with psoriasis to risankizumab after suboptimal response from secukinumab or ixekizumab treatment.

In two phase 3 trials, patients with moderate to severe hidradenitis suppurativa taking Cosentyx continued to improve beyond the primary endpoint analysis and up to 52 weeks, Novartis announced in a press release.

Patients with psoriatic arthritis demonstrate a “substantial prevalence” of radiographic damage at baseline, which is related to time since diagnosis, according to data published in Arthritis Research and Therapy.

MILAN — Secukinumab was effective in improving the signs and symptoms of moderate to severe hidradenitis suppurativa in two phase 3 clinical trials.

Secukinumab 300 mg is a safe and effective first-line biologic for patients with psoriatic arthritis, according to data from a biologic-naïve population based in the United States.

Real-world patients with psoriatic arthritis who receive secukinumab for 6 months maintain consistent proportions of minimal disease activity and demonstrate improved patient-reported outcomes, according to data.